Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Document Type
- Journal article (21)
Language
- English (21)
Keywords
- adrenocortical carcinoma (3)
- CYP2W1 (2)
- Cushing’s syndrome (2)
- FGFR (2)
- adrenal tumours (2)
- immunotherapy (2)
- metabolomics (2)
- 18F-FDG (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- ACTH (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CXCR4 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cushing's disease (1)
- Cushing’s disease (1)
- EMT (1)
- FGF-pathway (1)
- NMR (1)
- NR3C1 (1)
- PD-L1 (1)
- PET (1)
- PPGL (1)
- Positronen-Emissions-Tomografie (1)
- RNA Expression (1)
- RNAScope (1)
- SNP (1)
- SOAT1 (1)
- TKI (1)
- USP8 (1)
- [18F]FDG-PET-CT (1)
- abdominal lymph node metastases (1)
- adjuvant platinum-based chemotherapy (1)
- adrenal (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- autonomous cortisol secretion (1)
- biomarker (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- catecholamines (1)
- chemokine receptor (1)
- cholesterol metabolism (1)
- combination (1)
- confounders (1)
- dexamethasone suppression test (1)
- diagnosis (1)
- drug therapy (1)
- ectopic (1)
- endogenous hypercortisolism (1)
- epithelial markers (1)
- feature selection (1)
- glucocorticoid excess (1)
- high dose dexamethasone suppression test (1)
- hormones (1)
- hypercortisolism (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immune response (1)
- immunity (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- lymphocytes (1)
- machine learning (1)
- mass spectronomy (1)
- medullary thyroid carcinoma (1)
- mesenchymal markers (1)
- mitotane (1)
- molecular diagnostics (1)
- morbidity (1)
- mortality (1)
- multicenter (1)
- mutation triggers (1)
- normal adrenal glands (1)
- operation (1)
- paired (1)
- papillary thyroid carcinoma (PTC) (1)
- paraganglioma (1)
- parathyroid carcinoma (1)
- patient survival (1)
- pembrolizumab (1)
- personalized medicine (1)
- pheochromocytoma (1)
- phosphorylation (1)
- plasma (1)
- plasma NMR (1)
- positron emission tomography (1)
- preanalytical conditions (1)
- predictive marker (1)
- prognosis (1)
- prostate cancer (1)
- radical resection (1)
- radioiodine (1)
- radiotherapy (RT) (1)
- recurrence-free survival (1)
- repeated surgery (1)
- selpercatinib (1)
- surgical oncology (1)
- t-lymphocytes (1)
- targeted metabolomics (1)
- thyroid carcinoma (TC) (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase inhibitor (TKI) (1)
- unsupervised clustering (1)
- vandetanib (1)
Institute
- Medizinische Klinik und Poliklinik I (21) (remove)
Sonstige beteiligte Institutionen
Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma
(2020)
Chemokine receptors have a negative impact on tumor progression in several human cancers and have therefore been of interest for molecular imaging and targeted therapy. However, their clinical and prognostic significance in adrenocortical carcinoma (ACC) is unknown. The aim of this study was to evaluate the chemokine receptor profile in ACC and to analyse its association with clinicopathological characteristics and clinical outcome. A chemokine receptor profile was initially evaluated by quantitative PCR in 4 normal adrenals, 18 ACC samples and human ACC cell line NCI-H295. High expression of CXCR4 and CXCR7 in both healthy and malignant adrenal tissue and ACC cells was confirmed. In the next step, we analyzed the expression and cellular localization of CXCR4 and CXCR7 in ACC by immunohistochemistry in 187 and 84 samples, respectively. These results were correlated with clinicopathological parameters and survival outcome. We detected strong membrane expression of CXCR4 and CXCR7 in 50% of ACC samples. Strong cytoplasmic CXCR4 staining was more frequent among samples derived from metastases compared to primaries (p=0.01) and local recurrences (p=0.04). CXCR4 membrane staining positively correlated with proliferation index Ki67 (r=0.17, p=0.028). CXCR7 membrane staining negatively correlated with Ki67 (r=−0.254, p=0.03) but positively with tumor size (r=0.3, p=0.02). No differences in progression-free or overall survival were observed between patients with strong and weak staining intensities for CXCR4 or CXCR7. Taken together, high expression of CXCR4 and CXCR7 in both local tumors and metastases suggests that some ACC patients might benefit from CXCR4/CXCR7-targeted therapy.